HCC

General Cancer

Raymond Wadlow, MD, discusses interesting data presented for hepatocellular carcinoma at the 2018 Gastrointestinal Cancers Symposium.

Ahmed Omar Kaseb, MD, discusses the role of immunotherapy in the treatment landscape of HCC and the impact it could have in the presurgical setting.

Achieving an objective response to TKI therapy was associated with longer overall survival in patients with previously untreated hepatocellular carcinoma, according to findings of a retrospective analysis presented during the 2019 Gastrointestinal Cancers Symposium.

Cabozantinib has been approved by the FDA for the treatment of patients with hepatocellular carcinoma who previously received sorafenib, Exelixis, the company developing the agent, announced today.

Unresectable HCC with a History of Hepatitis C Virus

Kabir Mody, MD, discusses the importance of understanding sequencing in patients with hepatocellular carcinoma.

Kevin Staveley-O&rsquo;Carroll, MD, PhD,&nbsp;discusses how the field of HCC has advanced over the last few years and how a mouse model at the University of&nbsp;Missouri is being used to further investigate immunotherapy treatment options.<br /> &nbsp;

Michael J. Pishvaian, MD, PhD,&nbsp;discusses the potential for atezolizumab and bevacizumab in the frontline setting of HCC, as well the overall impact of immunotherapy in the treatment landscape of HCC.

A large pivotal phase III trial has been initiated to evaluate the potential for the first-line combination of cabozantinib and atezolizumab in comparison with standard-of-care sorafenib for patients with advanced hepatocellular carcinoma. Exelixis and Ipsen, the companies developing cabozantinib, announced the COSMIC-312 trial last week.